Floatz logo

IMIPENEM

Critical Illness

University of Illinois at ChicagoSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Critical Illness cohort.

Asset / SponsorPhaseRating
VITAMIN D
Massachusetts General Hospital
Phase 3BB
GLUCOSE, ANHYDROUS
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 4BB
L-Ofloxacin
Joel Thompson, PhD
Phase 4BB
CILASTATIN
University of Illinois at Chicago
Phase 4B
Inulin
Columbia University
Phase 2B

View all 14 →

Same molecule, other indications

IMIPENEM is also rated in:

bacterial pneumoniaDormant
BB
Indicative ·
65 / 100
View asset →
cystic fibrosisDormant
B
Indicative ·
59 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →